﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" returnVersion="2025v4.2">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2026-10-14T12:20:37+00:00</ReturnTs>
    <TaxPeriodEndDt>2025-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>135381590</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>BDO USA</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>200 PARK AVE 38TH FLOOR</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10166</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2025-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>134128413</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC</BusinessNameLine1Txt>
      </BusinessName>
      <BusinessNameControlTxt>GLOB</BusinessNameControlTxt>
      <PhoneNum>2122277540</PhoneNum>
      <USAddress>
        <AddressLine1Txt>80 PINE STREET FL 20</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10005</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>MELVIN SPIGELMAN</PersonNm>
      <PersonTitleTxt>PRESIDENT/CEO</PersonTitleTxt>
      <SignatureDt>2026-10-14</SignatureDt>
      <DiscussWithPaidPreparerInd>true</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <PreparerPersonGrp>
      <PreparerPersonNm>CHRISTINA PATTEN</PreparerPersonNm>
      <PTIN>P01972759</PTIN>
      <PhoneNum>2128858000</PhoneNum>
      <PreparationDt>2026-10-01</PreparationDt>
    </PreparerPersonGrp>
    <TaxYr>2025</TaxYr>
  </ReturnHeader>
  <ReturnData documentCnt="7">
    <IRS990 documentId="IRS990" softwareId="25022866" softwareVersionNum="2025v4.2">
      <DoingBusinessAsName>
        <BusinessNameLine1Txt>TB ALLIANCE</BusinessNameLine1Txt>
      </DoingBusinessAsName>
      <PrincipalOfcrBusinessName>
        <BusinessNameLine1Txt>MELVIN SPIGELMAN</BusinessNameLine1Txt>
      </PrincipalOfcrBusinessName>
      <USAddress>
        <AddressLine1Txt>80 PINE STREET FL 20</AddressLine1Txt>
        <CityNm>NEW YORK</CityNm>
        <StateAbbreviationCd>NY</StateAbbreviationCd>
        <ZIPCd>10005</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>76899215</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>false</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>WWW.TBALLIANCE.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>2000</FormationYr>
      <LegalDomicileStateCd>DE</LegalDomicileStateCd>
      <ActivityOrMissionDesc>TO ACCELERATE THE DISCOVERY &amp; DEVELOPMENT OF NEW DRUGS TO FACILITATE THE CONTROL OF TUBERCULOSIS THROUGHOUT THE WORLD AND THE ACCESSIBILITY OF THESE DRUGS TO THE GLOBAL COMMUNITY.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>11</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>10</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>49</TotalEmployeeCnt>
      <TotalVolunteersCnt>11</TotalVolunteersCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <PYContributionsGrantsAmt>52737212</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>41898401</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>0</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>9675203</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>7946317</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>1320142</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>2700338</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>63732557</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>52545056</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>359938</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>299510</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>17962003</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>17878606</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>0</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>1114379</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>43186842</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>35713220</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>61508783</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>53891336</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>2223774</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>-1346280</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>204316428</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>219365830</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>28006599</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>29669070</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>176309829</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>189696760</NetAssetsOrFundBalancesEOYAmt>
      <MissionDesc>TB ALLIANCE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF BETTER, FASTER-ACTING AND AFFORDABLE TUBERCULOSIS DRUGS THAT ARE AVAILABLE TO THOSE WHO NEED THEM.</MissionDesc>
      <SignificantNewProgramSrvcInd>false</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>false</SignificantChangeInd>
      <ExpenseAmt>40409317</ExpenseAmt>
      <GrantAmt>0</GrantAmt>
      <RevenueAmt>0</RevenueAmt>
      <Desc>RESEARCH AND DEVELOPMENT - TB ALLIANCE IS A NOT-FOR-PROFIT PRODUCT DEVELOPMENT PARTNERSHIP (PDP), UNIQUELY POSITIONED TO LEVERAGE A GLOBAL NETWORK OF PUBLIC AND PRIVATE PARTNERS TO MOST EFFICIENTLY ADVANCE TB DRUG DEVELOPMENT. A PDP BUILDS PARTNERSHIPS BETWEEN THE PUBLIC, PRIVATE, ACADEMIC, AND PHILANTHROPIC SECTORS TO DRIVE THE DEVELOPMENT OF NEW PRODUCTS FOR UNDERSERVED MARKETS. PDPS RETAIN DIRECT MANAGEMENT OVERSIGHT OF THEIR PROJECTS, THOUGH MUCH OF THE LABORATORY AND CLINICAL WORK IS DONE THROUGH EXTERNAL RESEARCH FACILITIES AND CONTRACTORS. WE COMBINE THE RESEARCH AND DEVELOPMENT EXPERTISE OF OUR STAFF WITH THE SKILLS AND RESOURCES OF OUR PARTNERS TO HARNESS THE MOST PROMISING SCIENCE WHEREVER IT MAY EXIST AROUND THE WORLD. THIS MODEL MINIMIZES COSTS, INCLUDING OVERHEAD AND INVESTMENTS IN INFRASTRUCTURE, WHILE OPTIMIZING SCIENTIFIC CAPABILITY TO SPEED NEW TB DRUG DEVELOPMENT. OUR BUSINESS MODEL AND DIVERSE PARTNERSHIPS ALLOW TB ALLIANCE TO LEVERAGE ADDITIONAL PARTNER SERVICES FOR EVERY DOLLAR INVESTED IN ITS PROGRAMS. NC-009 - NC-009 IS A PAN-PHASE 2 CLINICAL TRIAL INCORPORATING ELEMENTS OF PHASE 2A, B, AND C TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF A NEW EXPERIMENTAL COMPOUND, SORFEQUILINE (FORMERLY KNOWN AS TBAJ-876), WITH PRETOMANID AND LINEZOLID, COMPONENTS OF TB ALLIANCE'S BPAL REGIMEN. THIS REGIMEN HAS THE POTENTIAL TO SHORTEN AND IMPROVE TREATMENT FOR BOTH DRUG-SENSITIVE AND DRUG-RESISTANT FORMS OF TB. RESULTS FROM PRECLINICAL AND PHASE 1 STUDIES WERE PRESENTED AT THE 2023 UNION CONFERENCE ON LUNG HEALTH AND SHOWED THAT THE NEW COMPOUND, SORFEQUILINE, WHEN COMPARED WITH BEDAQUILINE (A TB MEDICINE IN THE SAME DRUG CLASS), ELIMINATED TB BACTERIA FASTER AND HAD A POTENTIALLY SAFER PROFILE. NC-009 TESTED DIFFERENT DOSES OF SORFEQUILINE IN COMBINATION WITH PRETOMANID AND LINEZOLID AGAINST THE CURRENT STANDARD OF CARE FOR DRUG-SENSITIVE TB - ISONIAZID, RIFAMPICIN, PYRAZINAMIDE, AND ETHEMBUTOL (HRZE). ANOTHER ARM OF THE TRIAL ALSO TESTED PRETOMANID AND LINEZOLID IN COMBINATION WITH BEDAQUILINE (BPAL), A REGIMEN NOW RECOMMENDED BY THE WORLD HEALTH ORGANIZATION TO TREAT SOME FORMS OF DR-TB, AGAINST DRUG-SENSITIVE TB. THE STUDY ENROLLED APPROXIMATELY 300 PARTICIPANTS WITH DRUG-SENSITIVE TB AT 21 CLINICAL TRIAL SITES IN FIVE COUNTRIES: GEORGIA, PHILIPPINES, SOUTH AFRICA, TANZANIA, AND UGANDA. THE RESULTS OF THE NC-009 CLINICAL TRIAL WERE PRESENTED AT THE 2025 UNION WORLD CONFERENCE ON LUNG HEALTH IN COPENHAGEN. THE RESULTS OF THE TRIAL SHOWED THAT, OVERALL, SORFEQUILINE HAD GREATER ACTIVITY THAN BEDAQUILINE. THE 100 MG SPAL REGIMEN HAD GREATER ACTIVITY AGAINST TB THAN THE STANDARD OF CARE HRZE (ISONIAZID, RIFAMPIN, PYRAZINAMIDE, AND ETHAMBUTOL), INDICATING THE POTENTIAL TO SHORTEN TREATMENT TIME FOR ACTIVE TB. IN ADDITION, THE SPAL REGIMEN HAD A COMPARABLE SAFETY PROFILE TO THE STANDARD OF CARE FOR PEOPLE WITH DRUG-SENSITIVE TB (DS-TB). Q203 - TELACEBEC (Q203) IS A FIRST IN-CLASS DRUG CANDIDATE AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION. Q203 TARGETS CYTOCHROME BC1 COMPLEX AND SHOWS POTENT ACTIVITY AGAINST MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB). Q203 HAS ALSO BEEN FOUND EFFECTIVE AGAINST BURULI ULCER (MYCOBACTERIUM ULCERANS), A CHRONIC, NECROTIZING DISEASE THAT AFFECTS SKIN AND SOMETIMES BONE AND CAN LEAD TO PERMANENT DEFORMITY AND LONG-TERM DISABILITY, AND LEPROSY (MYCOBACTERIUM LEPRAE). IN 2023, TB ALLIANCE IN-LICENSED Q203 FROM QURIENT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY BASED IN SOUTH KOREA. IN JULY 2024, A PHASE 2 PROOF-OF-CONCEPT STUDY WAS INITIATED TO EXPLORE THE USE OF TELACEBEC (Q203) TO TREAT BURULI ULCER. IF SUCCESSFUL, A SINGLE DRUG COULD CUT TREATMENT DURATION BY MORE THAN HALF. IN PARTNERSHIP WITH TB ALLIANCE AND WITH SUPPORT FROM QURIENT CO. LTD, PROFESSOR DANIEL O'BRIEN - A PROMINENT CLINICIAN-RESEARCHER AND EXPERT IN BURULI ULCER - IS LEADING THE STUDY AT BARWON HEALTH AND THE ROYAL MELBOURNE HOSPITAL IN AUSTRALIA. THE FIRST COHORT FOR THE TRIAL ENROLLED APPROXIMATELY 40 ADULT PATIENTS WITH BURULI ULCER WHO WILL RECEIVE 28 DAYS OF TELACEBEC (300MG) ONCE DAILY, FOLLOWED BY A YEAR OF OBSERVATION. PRELIMINARY RESULTS WERE REPORTED IN 2025 AND WERE POSITIVE. A SECOND COHORT OF PARTICIPANTS, ABOUT 80 ADDITIONAL PARTICIPANTS, WERE ENROLLED BY THE BEGINNING OF 2026 AND THE TRIAL IS CURRENTLY ONGOING. TBAJ-587 - THIS NEXT-GENERATION DIARYLQUINOLINE PROJECT HAS SHOWN POTENTIAL TO MAINTAIN BEDAQUILINE'S IMPRESSIVE ANTI-TB ACTIVITIES WHILE RETAINING ADDITIONAL IMPROVED PROPERTIES. TBAJ-587 IS BEING STUDIED THROUGH THE INNOVATIVE HEALTH INITIATIVE'S ERA4TB PROJECT AND, IN 2024, TBAJ-587 COMPLETED A PHASE I TRIAL DEMONSTRATING POSITIVE RESULTS. RESULTS PUBLICATIONS ARE UNDERWAY. AS OF AUGUST 2026, THE PHASE 2 TRIAL, NAMED SYNERGY, WILL SOON BEGIN ENROLLMENT IN SOUTH AFRICA UNDER THE INNOVATIVE HEALTH INITIATIVE'S UNITE4TB PROGRAM.</Desc>
      <ProgSrvcAccomActy2Grp>
        <ExpenseAmt>5645557</ExpenseAmt>
        <GrantAmt>299510</GrantAmt>
        <RevenueAmt>0</RevenueAmt>
        <Desc>PUBLIC AFFAIRS AND POLICY - TB ALLIANCE MAINTAINS CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY FOR THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR ON THE DEVELOPMENT OF THESE MEDICINES. TB ALLIANCE CONTINUES TO PURSUE AN EXPLICIT COMMITMENT TO OUR "AAA MANDATE" - THAT ALL NEW PRODUCTS WILL BE ADOPTED, AVAILABLE AND AFFORDABLE TO THOSE WITH TB.</Desc>
      </ProgSrvcAccomActy2Grp>
      <ProgSrvcAccomActy3Grp>
        <ExpenseAmt>811284</ExpenseAmt>
        <GrantAmt>0</GrantAmt>
        <RevenueAmt>0</RevenueAmt>
        <Desc>BUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS.</Desc>
      </ProgSrvcAccomActy3Grp>
      <TotalProgramServiceExpensesAmt>46866158</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="IRS990ScheduleA">true</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="IRS990ScheduleB">true</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd>false</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd>false</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd referenceDocumentId="IRS990ScheduleC">false</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd>false</DonorAdvisedFundInd>
      <ConservationEasementsInd>false</ConservationEasementsInd>
      <CollectionsOfArtInd>false</CollectionsOfArtInd>
      <CreditCounselingInd>false</CreditCounselingInd>
      <DonorRstrOrQuasiEndowmentsInd>false</DonorRstrOrQuasiEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="IRS990ScheduleD">true</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="IRS990ScheduleD">true</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd>false</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="IRS990ScheduleD">true</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="IRS990ScheduleD">true</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="IRS990ScheduleD">true</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="IRS990ScheduleD">true</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd>false</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>false</SchoolOperatingInd>
      <ForeignOfficeInd>true</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="IRS990ScheduleF">true</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="IRS990ScheduleF">true</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd>false</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd>false</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd>false</FundraisingActivitiesInd>
      <GamingActivitiesInd>false</GamingActivitiesInd>
      <OperateHospitalInd>false</OperateHospitalInd>
      <GrantsToOrganizationsInd>false</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd>false</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="IRS990ScheduleJ">true</ScheduleJRequiredInd>
      <TaxExemptBondsInd>false</TaxExemptBondsInd>
      <EscrowAccountInd>false</EscrowAccountInd>
      <OnBehalfOfIssuerInd>false</OnBehalfOfIssuerInd>
      <EngagedInExcessBenefitTransInd>false</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>false</PYExcessBenefitTransInd>
      <LoanOutstandingInd>false</LoanOutstandingInd>
      <GrantToRelatedPersonInd>false</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>false</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>false</BusinessRlnWithFamMemInd>
      <BusinessRlnWith35CtrlEntInd>false</BusinessRlnWith35CtrlEntInd>
      <DeductibleNonCashContriInd>false</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd>false</DeductibleArtContributionInd>
      <TerminateOperationsInd>false</TerminateOperationsInd>
      <PartialLiquidationInd>false</PartialLiquidationInd>
      <DisregardedEntityInd>false</DisregardedEntityInd>
      <RelatedEntityInd>false</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>false</RelatedOrganizationCtrlEntInd>
      <TransactionWithControlEntInd>false</TransactionWithControlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd>false</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd>false</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>true</ScheduleORequiredInd>
      <IRPDocumentCnt>50</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <BackupWthldComplianceInd>true</BackupWthldComplianceInd>
      <EmployeeCnt>49</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>true</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>false</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>false</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>false</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>false</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>false</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>false</QuidProQuoContributionsInd>
      <Form8282PropertyDisposedOfInd>false</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>false</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>false</PayPremiumsPrsnlBnftCntrctInd>
      <IndoorTanningServicesInd>false</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>false</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>false</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>11</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>10</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>false</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>false</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>false</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>false</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>false</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>false</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>false</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>true</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>true</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>false</OfficerMailingAddressInd>
      <LocalChaptersInd>false</LocalChaptersInd>
      <PoliciesReferenceChaptersInd>false</PoliciesReferenceChaptersInd>
      <Form990ProvidedToGvrnBodyInd>true</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>true</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>true</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>true</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>true</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>true</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>true</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>true</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>false</InvestmentInJointVentureInd>
      <WrittenPolicyOrProcedureInd>false</WrittenPolicyOrProcedureInd>
      <StatesWhereCopyOfReturnIsFldCd>NY</StatesWhereCopyOfReturnIsFldCd>
      <OwnWebsiteInd>X</OwnWebsiteInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <BusinessName>
          <BusinessNameLine1Txt>ANGELA VANDERPLOEG</BusinessNameLine1Txt>
        </BusinessName>
        <PhoneNum>2122277540</PhoneNum>
        <USAddress>
          <AddressLine1Txt>80 PINE STREET 20TH FLOOR</AddressLine1Txt>
          <CityNm>NEW YORK</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10005</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <PersonNm>DAVID NORTON</PersonNm>
        <TitleTxt>CHAIR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ERIC GOOSBY</PersonNm>
        <TitleTxt>VICE-CHAIR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MELVIN SPIGELMAN</PersonNm>
        <TitleTxt>PRESIDENT/CEO</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>979462</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>115515</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>AKSHAY VAISHNAW</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ANN TAYLOR</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KIM SCHWARTZ</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MITCHELL WARREN</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>RASHA HIBRI</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>RATAN WATAL</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SRISHTI GUPTA</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SUNDAR KODIYALAM</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>3.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ANGELA VANDERPLOEG</PersonNm>
        <TitleTxt>TREASURER/CFO</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>442294</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>108145</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>COLLEEN PERO</PersonNm>
        <TitleTxt>SECRETARY/CAO</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>489385</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>73926</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>EUGENE SUN</PersonNm>
        <TitleTxt>SR. VP, RESEARCH &amp; DEVELOPMENT</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>604382</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>98971</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MARIA BEUMONT</PersonNm>
        <TitleTxt>VP, CHIEF MEDICAL OFFICER</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>514534</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>86878</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>NADER FOTOUHI</PersonNm>
        <TitleTxt>SR. VP, CHIEF SCIENTIFIC OFFICER</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>586613</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>121980</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>PIETRO O TURILLI</PersonNm>
        <TitleTxt>SR. VP, EXTERNAL AFFAIRS (THRU 11/30/25)</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>368685</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>94564</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KATHLEEN SCHOSTACK</PersonNm>
        <TitleTxt>SR. VP, PROGRAM &amp; ALLIANCE MANAGEMENT (THRU 08/31/25)</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>379734</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>63868</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>RAJNEESH TANEJA</PersonNm>
        <TitleTxt>VP, PHARMACEUTICAL PRODUCT DEVELOPMENT</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>392025</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>84435</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>ROBERT LORETTE</PersonNm>
        <TitleTxt>SR. VP, BUSINESS DEVELOPMENT</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>467971</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>90517</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SALAH FORAIDA</PersonNm>
        <TitleTxt>SR. DIRECTOR, MEDICAL AFFAIRS</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>446439</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>54163</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SANDEEP JUNEJA</PersonNm>
        <TitleTxt>SR. VP, MARKET ACCESS</TitleTxt>
        <AverageHoursPerWeekRt>45.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>435088</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>107467</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>6106612</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>1100429</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>42</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>false</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>true</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>false</CompensationFromOtherSrcsInd>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>PPD DEVELOPMENT LP</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>26361 NETWORK PLACE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60673</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>GLOBAL CRO</ServicesDesc>
        <CompensationAmt>3821476</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>WUXI APPTEC (HONGKONG) LIMITED</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <ForeignAddress>
            <AddressLine1Txt>UNIT C 20/F NO 998 CANTON RD</AddressLine1Txt>
            <CityNm>KOWLOON</CityNm>
            <CountryCd>HK</CountryCd>
          </ForeignAddress>
        </ContractorAddress>
        <ServicesDesc>INTEGRATED R&amp;D SERVICES</ServicesDesc>
        <CompensationAmt>3048268</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>RTI INTERNATIONAL</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>PO BOX 900002</AddressLine1Txt>
            <CityNm>RALEIGH</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>27675</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>INTEGRATED R&amp;D SERVICES</ServicesDesc>
        <CompensationAmt>1247412</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>GLAXOSMITHKLINE INVESTIGACIN Y DESARROLLO SL</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <ForeignAddress>
            <AddressLine1Txt>28760 TRES CANTOS</AddressLine1Txt>
            <CityNm>MADRID</CityNm>
            <CountryCd>SP</CountryCd>
          </ForeignAddress>
        </ContractorAddress>
        <ServicesDesc>EXTERNAL MINI PORTFOLIOS</ServicesDesc>
        <CompensationAmt>1200000</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <BusinessName>
            <BusinessNameLine1Txt>JOHNS HOPKINS UNIVERSITY CENTRAL</BusinessNameLine1Txt>
          </BusinessName>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>12529 COLLECTIONS CENTER DRIVE</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60693</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>INTEGRATED R&amp;D SERVICES</ServicesDesc>
        <CompensationAmt>1184064</CompensationAmt>
      </ContractorCompensationGrp>
      <CntrctRcvdGreaterThan100KCnt>70</CntrctRcvdGreaterThan100KCnt>
      <GovernmentGrantsAmt>24601930</GovernmentGrantsAmt>
      <AllOtherContributionsAmt>17296471</AllOtherContributionsAmt>
      <TotalContributionsAmt>41898401</TotalContributionsAmt>
      <TotalOthProgramServiceRevGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </TotalOthProgramServiceRevGrp>
      <TotalProgramServiceRevenueAmt>0</TotalProgramServiceRevenueAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>3189504</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>3189504</ExclusionAmt>
      </InvestmentIncomeGrp>
      <RoyaltiesRevenueGrp>
        <TotalRevenueColumnAmt>572608</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>572608</ExclusionAmt>
      </RoyaltiesRevenueGrp>
      <RentalIncomeOrLossGrp>
        <RealAmt>0</RealAmt>
        <PersonalAmt>0</PersonalAmt>
      </RentalIncomeOrLossGrp>
      <GrossAmountSalesAssetsGrp>
        <SecuritiesAmt>29110972</SecuritiesAmt>
      </GrossAmountSalesAssetsGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <SecuritiesAmt>24354159</SecuritiesAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>4756813</SecuritiesAmt>
        <OtherAmt>0</OtherAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>4756813</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>4756813</ExclusionAmt>
      </NetGainOrLossInvestmentsGrp>
      <NetIncmFromFundraisingEvtGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </NetIncmFromFundraisingEvtGrp>
      <OtherRevenueMiscGrp>
        <Desc>MISCELLANEOUS INCOME</Desc>
        <BusinessCd>900099</BusinessCd>
        <TotalRevenueColumnAmt>2127730</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>2127730</ExclusionAmt>
      </OtherRevenueMiscGrp>
      <MiscellaneousRevenueGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </MiscellaneousRevenueGrp>
      <OtherRevenueTotalAmt>2127730</OtherRevenueTotalAmt>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>52545056</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>10646655</ExclusionAmt>
      </TotalRevenueGrp>
      <InfoInScheduleOPartIXInd>X</InfoInScheduleOPartIXInd>
      <ForeignGrantsGrp>
        <TotalAmt>299510</TotalAmt>
        <ProgramServicesAmt>299510</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <BenefitsToMembersGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
      </BenefitsToMembersGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>4698570</TotalAmt>
        <ProgramServicesAmt>3043991</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1121846</ManagementAndGeneralAmt>
        <FundraisingAmt>532733</FundraisingAmt>
      </CompCurrentOfcrDirectorsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>10108129</TotalAmt>
        <ProgramServicesAmt>8211807</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1725071</ManagementAndGeneralAmt>
        <FundraisingAmt>171251</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <PensionPlanContributionsGrp>
        <TotalAmt>927578</TotalAmt>
        <ProgramServicesAmt>760445</ProgramServicesAmt>
        <ManagementAndGeneralAmt>151498</ManagementAndGeneralAmt>
        <FundraisingAmt>15635</FundraisingAmt>
      </PensionPlanContributionsGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>1364772</TotalAmt>
        <ProgramServicesAmt>1117537</ProgramServicesAmt>
        <ManagementAndGeneralAmt>238435</ManagementAndGeneralAmt>
        <FundraisingAmt>8800</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>779557</TotalAmt>
        <ProgramServicesAmt>598124</ProgramServicesAmt>
        <ManagementAndGeneralAmt>148069</ManagementAndGeneralAmt>
        <FundraisingAmt>33364</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesLegalGrp>
        <TotalAmt>787905</TotalAmt>
        <ProgramServicesAmt>668194</ProgramServicesAmt>
        <ManagementAndGeneralAmt>119711</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForServicesLegalGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>117674</TotalAmt>
        <ProgramServicesAmt>15600</ProgramServicesAmt>
        <ManagementAndGeneralAmt>102074</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForServicesAccountingGrp>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>427243</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>427243</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>6327742</TotalAmt>
        <ProgramServicesAmt>5823234</ProgramServicesAmt>
        <ManagementAndGeneralAmt>294800</ManagementAndGeneralAmt>
        <FundraisingAmt>209708</FundraisingAmt>
      </FeesForServicesOtherGrp>
      <OfficeExpensesGrp>
        <TotalAmt>247274</TotalAmt>
        <ProgramServicesAmt>23193</ProgramServicesAmt>
        <ManagementAndGeneralAmt>223901</ManagementAndGeneralAmt>
        <FundraisingAmt>180</FundraisingAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>1151825</TotalAmt>
        <ProgramServicesAmt>481345</ProgramServicesAmt>
        <ManagementAndGeneralAmt>645239</ManagementAndGeneralAmt>
        <FundraisingAmt>25241</FundraisingAmt>
      </InformationTechnologyGrp>
      <OccupancyGrp>
        <TotalAmt>1368458</TotalAmt>
        <ProgramServicesAmt>1026135</ProgramServicesAmt>
        <ManagementAndGeneralAmt>293931</ManagementAndGeneralAmt>
        <FundraisingAmt>48392</FundraisingAmt>
      </OccupancyGrp>
      <TravelGrp>
        <TotalAmt>999138</TotalAmt>
        <ProgramServicesAmt>805109</ProgramServicesAmt>
        <ManagementAndGeneralAmt>158536</ManagementAndGeneralAmt>
        <FundraisingAmt>35493</FundraisingAmt>
      </TravelGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>120244</TotalAmt>
        <ProgramServicesAmt>110542</ProgramServicesAmt>
        <ManagementAndGeneralAmt>8868</ManagementAndGeneralAmt>
        <FundraisingAmt>834</FundraisingAmt>
      </ConferencesMeetingsGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>276848</TotalAmt>
        <ProgramServicesAmt>202937</ProgramServicesAmt>
        <ManagementAndGeneralAmt>64079</ManagementAndGeneralAmt>
        <FundraisingAmt>9832</FundraisingAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>201787</TotalAmt>
        <ProgramServicesAmt>42014</ProgramServicesAmt>
        <ManagementAndGeneralAmt>159773</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>R&amp;D PROJECT EXPENSES</Desc>
        <TotalAmt>23586534</TotalAmt>
        <ProgramServicesAmt>23586534</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>DUES AND SUBSCRIPTIONS</Desc>
        <TotalAmt>100548</TotalAmt>
        <ProgramServicesAmt>49907</ProgramServicesAmt>
        <ManagementAndGeneralAmt>27725</ManagementAndGeneralAmt>
        <FundraisingAmt>22916</FundraisingAmt>
      </OtherExpensesGrp>
      <AllOtherExpensesGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </AllOtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>53891336</TotalAmt>
        <ProgramServicesAmt>46866158</ProgramServicesAmt>
        <ManagementAndGeneralAmt>5910799</ManagementAndGeneralAmt>
        <FundraisingAmt>1114379</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <BOYAmt>34377400</BOYAmt>
        <EOYAmt>20839065</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <PledgesAndGrantsReceivableGrp>
        <BOYAmt>6609856</BOYAmt>
        <EOYAmt>5970313</EOYAmt>
      </PledgesAndGrantsReceivableGrp>
      <AccountsReceivableGrp>
        <BOYAmt>1081288</BOYAmt>
        <EOYAmt>1230556</EOYAmt>
      </AccountsReceivableGrp>
      <ReceivablesFromOfficersEtcGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </ReceivablesFromOfficersEtcGrp>
      <RcvblFromDisqualifiedPrsnGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </RcvblFromDisqualifiedPrsnGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>1196922</BOYAmt>
        <EOYAmt>1259801</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>1723113</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>673845</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>1320475</BOYAmt>
        <EOYAmt>1049268</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>80443114</BOYAmt>
        <EOYAmt>88304886</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <InvestmentsOtherSecuritiesGrp>
        <BOYAmt>64373689</BOYAmt>
        <EOYAmt>86595017</EOYAmt>
      </InvestmentsOtherSecuritiesGrp>
      <InvestmentsProgramRelatedGrp>
        <BOYAmt>0</BOYAmt>
      </InvestmentsProgramRelatedGrp>
      <OtherAssetsTotalGrp>
        <BOYAmt>14913684</BOYAmt>
        <EOYAmt>14116924</EOYAmt>
      </OtherAssetsTotalGrp>
      <TotalAssetsGrp>
        <BOYAmt>204316428</BOYAmt>
        <EOYAmt>219365830</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>8739913</BOYAmt>
        <EOYAmt>8417258</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <DeferredRevenueGrp>
        <BOYAmt>2621045</BOYAmt>
        <EOYAmt>5500744</EOYAmt>
      </DeferredRevenueGrp>
      <LoansFromOfficersDirectorsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </LoansFromOfficersDirectorsGrp>
      <OtherLiabilitiesGrp>
        <BOYAmt>16645641</BOYAmt>
        <EOYAmt>15751068</EOYAmt>
      </OtherLiabilitiesGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>28006599</BOYAmt>
        <EOYAmt>29669070</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsFASB117Ind>X</OrganizationFollowsFASB117Ind>
      <NoDonorRestrictionNetAssetsGrp>
        <BOYAmt>176309829</BOYAmt>
        <EOYAmt>189696760</EOYAmt>
      </NoDonorRestrictionNetAssetsGrp>
      <DonorRestrictionNetAssetsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </DonorRestrictionNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>176309829</BOYAmt>
        <EOYAmt>189696760</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>204316428</BOYAmt>
        <EOYAmt>219365830</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <InfoInScheduleOPartXIInd>X</InfoInScheduleOPartXIInd>
      <ReconcilationRevenueExpnssAmt>-1346280</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>14777632</NetUnrlzdGainsLossesInvstAmt>
      <OtherChangesInNetAssetsAmt>-44421</OtherChangesInNetAssetsAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>false</AccountantCompileOrReviewInd>
      <FSAuditedInd>true</FSAuditedInd>
      <AuditCommitteeInd>true</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>true</FederalGrantAuditRequiredInd>
      <FederalGrantAuditPerformedInd>true</FederalGrantAuditPerformedInd>
    </IRS990>
    <IRS990ScheduleA documentId="IRS990ScheduleA" softwareId="25022866" softwareVersionNum="2025v4.2">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>58183286</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>52646326</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>49796816</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>52737212</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>41898401</CurrentTaxYearAmt>
        <TotalAmt>255262041</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TaxRevLeviedOrgnztnlBnft170Grp>
        <CurrentTaxYearAmt>0</CurrentTaxYearAmt>
        <TotalAmt>0</TotalAmt>
      </TaxRevLeviedOrgnztnlBnft170Grp>
      <GovtFurnSrvcFcltsVl170Grp>
        <CurrentTaxYearAmt>0</CurrentTaxYearAmt>
        <TotalAmt>0</TotalAmt>
      </GovtFurnSrvcFcltsVl170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>58183286</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>52646326</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>49796816</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>52737212</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>41898401</CurrentTaxYearAmt>
        <TotalAmt>255262041</TotalAmt>
      </TotalCalendarYear170Grp>
      <SubstantialContributorsTotAmt>82192682</SubstantialContributorsTotAmt>
      <PublicSupportTotal170Amt>173069358</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>77877</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>2686767</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>8339176</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>6406586</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>3762112</CurrentTaxYearAmt>
        <TotalAmt>21272518</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <UnrelatedBusinessNetIncm170Grp>
        <CurrentTaxYearAmt>0</CurrentTaxYearAmt>
        <TotalAmt>0</TotalAmt>
      </UnrelatedBusinessNetIncm170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>392216</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>901316</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>1981851</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>932353</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>2127730</CurrentTaxYearAmt>
        <TotalAmt>6335466</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>282870025</TotalSupportAmt>
      <GrossReceiptsRltdActivitiesAmt>0</GrossReceiptsRltdActivitiesAmt>
      <PublicSupportCY170Pct>0.61183</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.62836</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
      <Form990ScheduleAPartVIGrp>
        <FormAndLineReferenceDesc>SCHEDULE A, PART II, LINE 10 OTHER INCOME</FormAndLineReferenceDesc>
        <ExplanationTxt>DESCRIPTION - , COLUMN A - 392216.0, COLUMN B - 901316.0, COLUMN C - 1981851.0, COLUMN D - 932353.0, COLUMN E - 2127730.0, COLUMN F - 6335466.0;</ExplanationTxt>
      </Form990ScheduleAPartVIGrp>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="IRS990ScheduleB" softwareId="25022866" softwareVersionNum="2025v4.2">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleD documentId="IRS990ScheduleD" softwareId="25022866" softwareVersionNum="2025v4.2">
      <LeaseholdImprovementsGrp>
        <OtherCostOrOtherBasisAmt>636260</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>101369</DepreciationAmt>
        <BookValueAmt>534891</BookValueAmt>
      </LeaseholdImprovementsGrp>
      <EquipmentGrp>
        <OtherCostOrOtherBasisAmt>99819</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>80965</DepreciationAmt>
        <BookValueAmt>18854</BookValueAmt>
      </EquipmentGrp>
      <OtherLandBuildingsGrp>
        <OtherCostOrOtherBasisAmt>987034</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>491511</DepreciationAmt>
        <BookValueAmt>495523</BookValueAmt>
      </OtherLandBuildingsGrp>
      <TotalBookValueLandBuildingsAmt>1049268</TotalBookValueLandBuildingsAmt>
      <OtherSecuritiesGrp>
        <Desc>CLOSELY-HELD EQUITY INTERESTS</Desc>
      </OtherSecuritiesGrp>
      <OtherSecuritiesGrp>
        <Desc>FINANCIAL DERIVATIVES</Desc>
      </OtherSecuritiesGrp>
      <OtherSecuritiesGrp>
        <Desc>INVESTMENTS IN LIMITED PARTNERSHIP</Desc>
        <BookValueAmt>86595017</BookValueAmt>
        <MethodValuationCd>F</MethodValuationCd>
      </OtherSecuritiesGrp>
      <TotalBookValueSecuritiesAmt>86595017</TotalBookValueSecuritiesAmt>
      <OtherAssetsOrgGrp>
        <Desc>RIGHT-OF-USE ASSETS - OPERATING LEASES</Desc>
        <BookValueAmt>13971690</BookValueAmt>
      </OtherAssetsOrgGrp>
      <OtherAssetsOrgGrp>
        <Desc>SECURITY DEPOSITS</Desc>
        <BookValueAmt>145234</BookValueAmt>
      </OtherAssetsOrgGrp>
      <TotalBookValueOtherAssetsAmt>14116924</TotalBookValueOtherAssetsAmt>
      <OtherLiabilitiesOrgGrp>
        <Desc>FEDERAL INCOME TAXES</Desc>
      </OtherLiabilitiesOrgGrp>
      <OtherLiabilitiesOrgGrp>
        <Desc>OPERATING LEASE LIABILITIES</Desc>
        <Amt>15751068</Amt>
      </OtherLiabilitiesOrgGrp>
      <TotalLiabilityAmt>15751068</TotalLiabilityAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <TotalRevEtcAuditedFinclStmtAmt>66895445</TotalRevEtcAuditedFinclStmtAmt>
      <NetUnrealizedGainsInvstAmt>14777632</NetUnrealizedGainsInvstAmt>
      <OtherRevenueAmt>0</OtherRevenueAmt>
      <RevenueNotReportedAmt>14777632</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>52117813</RevenueSubtotalAmt>
      <InvestmentExpensesNotIncldAmt>427243</InvestmentExpensesNotIncldAmt>
      <OtherRevenuesNotIncludedAmt>0</OtherRevenuesNotIncludedAmt>
      <RevenueNotReportedFinclStmtAmt>427243</RevenueNotReportedFinclStmtAmt>
      <TotalRevenuePerForm990Amt>52545056</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>53464093</TotExpnsEtcAuditedFinclStmtAmt>
      <OtherExpensesIncludedAmt>0</OtherExpensesIncludedAmt>
      <ExpensesNotReportedAmt>0</ExpensesNotReportedAmt>
      <ExpensesSubtotalAmt>53464093</ExpensesSubtotalAmt>
      <InvestmentExpensesNotIncld2Amt>427243</InvestmentExpensesNotIncld2Amt>
      <OtherExpensesNotIncludedAmt>0</OtherExpensesNotIncludedAmt>
      <ExpensesNotRptFinclStmtAmt>427243</ExpensesNotRptFinclStmtAmt>
      <TotalExpensesPerForm990Amt>53891336</TotalExpensesPerForm990Amt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE D, PART X, LINE 2 FIN 48 (ASC 740) FOOTNOTE</FormAndLineReferenceDesc>
        <ExplanationTxt>TB ALLIANCE IS SUBJECT TO THE PROVISIONS OF THE FINANCIAL ACCOUNTING STANDARDS BOARD'S (FASB) ACCOUNTING STANDARDS CODIFICATION (ASC 740), INCOME TAXES (ASC 740), AS IT RELATES TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. TB ALLIANCE DOES NOT BELIEVE IT HAS TAKEN ANY MATERIAL UNCERTAIN TAX POSITIONS AND, DUE TO ITS GENERAL NOT-FOR-PROFIT STATUS, MANAGEMENT BELIEVES ASC 740 HAS NOT HAD, AND IS NOT ANTICIPATED TO HAVE, A MATERIAL IMPACT ON TB ALLIANCE'S FINANCIAL STATEMENTS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="IRS990ScheduleF" softwareId="25022866" softwareVersionNum="2025v4.2">
      <GrantRecordsMaintainedInd>true</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>CENTRAL AMERICA AND THE CARIBBEAN</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>1</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>CONSULTING SERVICES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>8751</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EAST ASIA AND THE PACIFIC</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>R&amp;D RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>3784435</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EAST ASIA AND THE PACIFIC</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>13</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>CONSULTING SERVICES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>1015375</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EAST ASIA AND THE PACIFIC</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>ADMINISTRATIVE EXP.</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>14442</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND AND GREENLAND)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>R&amp;D RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>4645787</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND AND GREENLAND)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>16</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>CONSULTING SERVICES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>1658247</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND AND GREENLAND)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>ADMINISTRATIVE EXP.</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>108002</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND AND GREENLAND)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>GRANTMAKING</TypeOfActivitiesConductedTxt>
        <RegionTotalExpendituresAmt>18693</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>MIDDLE EAST AND NORTH AFRICA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>ADMINISTRATIVE EXP.</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>14767</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>NORTH AMERICA (CANADA &amp; MEXICO ONLY)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>R&amp;D RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>132600</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>NORTH AMERICA (CANADA &amp; MEXICO ONLY)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>2</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>CONSULTING SERVICES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>25163</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>NORTH AMERICA (CANADA &amp; MEXICO ONLY)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>ADMINISTRATIVE EXP.</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>17971</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>RUSSIA AND NEIGHBORING STATES</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>4</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>CONSULTING SERVICES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>150797</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>RUSSIA AND NEIGHBORING STATES</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>R&amp;D RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>120005</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>RUSSIA AND NEIGHBORING STATES</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>GRANTMAKING</TypeOfActivitiesConductedTxt>
        <RegionTotalExpendituresAmt>17000</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>RUSSIA AND NEIGHBORING STATES</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>ADMINISTRATIVE EXP.</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>8544</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SOUTH AMERICA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>5</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>CONSULTING SERVICES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>111776</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SOUTH AMERICA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>R&amp;D RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>24584</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SOUTH AMERICA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>ADMINISTRATIVE EXPENSES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>1409</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SOUTH ASIA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>R&amp;D RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>1391350</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SOUTH ASIA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>15</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>CONSULTING SERVICES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>360377</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SOUTH ASIA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>ADMINISTRATIVE EXPENSES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>4757</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SUB-SAHARAN AFRICA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>R&amp;D RESEARCH</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>2269752</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SUB-SAHARAN AFRICA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>6</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>SALARY EXPENSES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>852242</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SUB-SAHARAN AFRICA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>GRANTMAKING</TypeOfActivitiesConductedTxt>
        <RegionTotalExpendituresAmt>263817</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SUB-SAHARAN AFRICA</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>5</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>CONSULTING SERVICES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>63499</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>SUB-SAHARAN AFRICA</RegionTxt>
        <OfficesCnt>1</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>PROGRAM SERVICES</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>ADMINISTRATIVE EXPENSES</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>60235</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalOfficesCnt>0</SubtotalOfficesCnt>
      <SubtotalEmployeesCnt>36</SubtotalEmployeesCnt>
      <ContinuationTotalOfficeCnt>1</ContinuationTotalOfficeCnt>
      <ContinuationTotalEmployeeCnt>31</ContinuationTotalEmployeeCnt>
      <TotalOfficeCnt>1</TotalOfficeCnt>
      <TotalEmployeeCnt>67</TotalEmployeeCnt>
      <SubtotalSpentAmt>11740579</SubtotalSpentAmt>
      <ContinuationSpentAmt>5403798</ContinuationSpentAmt>
      <TotalSpentAmt>17144377</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>EUROPE (INCLUDING ICELAND AND GREENLAND)</RegionTxt>
        <PurposeOfGrantTxt>COMMUNITY ENENGAGEMENT</PurposeOfGrantTxt>
        <CashGrantAmt>18693</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE</MannerOfCashDisbursementTxt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>RUSSIA AND NEIGHBORING STATES</RegionTxt>
        <PurposeOfGrantTxt>COMMUNITY ENENGAGEMENT</PurposeOfGrantTxt>
        <CashGrantAmt>17000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE</MannerOfCashDisbursementTxt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>SUB-SAHARAN AFRICA</RegionTxt>
        <PurposeOfGrantTxt>COMMUNITY ENENGAGEMENT</PurposeOfGrantTxt>
        <CashGrantAmt>263817</CashGrantAmt>
        <MannerOfCashDisbursementTxt>WIRE</MannerOfCashDisbursementTxt>
      </GrantsToOrgOutsideUSGrp>
      <Total501c3OrgCnt>3</Total501c3OrgCnt>
      <TotalOtherOrgCnt>0</TotalOtherOrgCnt>
      <TransferToForeignCorpInd>false</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>false</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>false</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>false</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>false</ForeignPartnershipInd>
      <BoycottCountriesInd>false</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE F, PART I, LINE 2 PROCEDURES FOR MONITORING USE OF GRANT FUNDS</FormAndLineReferenceDesc>
        <ExplanationTxt>THE GRANTEE IS REQUIRED TO PROVIDE THE ORGANIZATION WITH AN ITEMIZED ACCOUNTING OF EXPENDITURES FOR THE PROJECT AND A REPORT ON THE PROGRESS OF THE PROJECT ON A SCHEDULE SPECIFIED IN THE AGREEMENT. THIS REQUIREMENT IS OUTLINED IN THE SIGNED AGREEMENT BETWEEN BOTH PARTIES.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE F, PART I, LINE 3 METHOD USED TO ACCOUNT FOR EXPENDITURES ON ORG'S FINANCIAL STATEMENTS</FormAndLineReferenceDesc>
        <ExplanationTxt>CENTRAL AMERICA AND THE CARIBBEAN-ACCRUAL; EAST ASIA AND THE PACIFIC-ACCRUAL; EUROPE (INCLUDING ICELAND AND GREENLAND)-ACCRUAL; MIDDLE EAST AND NORTH AFRICA-ACCRUAL; NORTH AMERICA (CANADA &amp; MEXICO ONLY)-ACCRUAL; RUSSIA AND NEIGHBORING STATES-ACCRUAL; SOUTH AMERICA-ACCRUAL; SOUTH ASIA-ACCRUAL; SUB-SAHARAN AFRICA-ACCRUAL</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE F, PART II, LINE 1 METHOD USED TO ACCOUNT FOR EXPENDITURES ON ORG'S FINANCIAL STATEMENTS</FormAndLineReferenceDesc>
        <ExplanationTxt>EUROPE (INCLUDING ICELAND AND GREENLAND)-ACCRUAL; RUSSIA AND NEIGHBORING STATES-ACCRUAL; SUB-SAHARAN AFRICA-ACCRUAL</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleJ documentId="IRS990ScheduleJ" softwareId="25022866" softwareVersionNum="2025v4.2">
      <CompensationCommitteeInd>X</CompensationCommitteeInd>
      <IndependentConsultantInd>X</IndependentConsultantInd>
      <Form990OfOtherOrganizationsInd>X</Form990OfOtherOrganizationsInd>
      <CompensationSurveyInd>X</CompensationSurveyInd>
      <BoardOrCommitteeApprovalInd>X</BoardOrCommitteeApprovalInd>
      <SeverancePaymentInd>false</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>false</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>false</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>false</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>false</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>false</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>false</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>true</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>false</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>MELVIN SPIGELMAN</PersonNm>
        <TitleTxt>PRESIDENT/CEO</TitleTxt>
        <BaseCompensationFilingOrgAmt>688096</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>291366</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>70000</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>45515</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>1094977</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>COLLEEN PERO</PersonNm>
        <TitleTxt>SECRETARY/CAO</TitleTxt>
        <BaseCompensationFilingOrgAmt>386933</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>102452</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>48190</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>25736</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>563311</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>ANGELA VANDERPLOEG</PersonNm>
        <TitleTxt>TREASURER/CFO</TitleTxt>
        <BaseCompensationFilingOrgAmt>349263</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>93031</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>44119</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>64026</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>550439</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>NADER FOTOUHI</PersonNm>
        <TitleTxt>SR. VP, CHIEF SCIENTIFIC OFFICER</TitleTxt>
        <BaseCompensationFilingOrgAmt>463255</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>123358</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>58300</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>63680</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>708593</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>EUGENE SUN</PersonNm>
        <TitleTxt>SR. VP, RESEARCH &amp; DEVELOPMENT</TitleTxt>
        <BaseCompensationFilingOrgAmt>478354</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>126028</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>55091</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>43880</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>703353</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>MARIA BEUMONT</PersonNm>
        <TitleTxt>VP, CHIEF MEDICAL OFFICER</TitleTxt>
        <BaseCompensationFilingOrgAmt>423892</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>90642</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>46500</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>40378</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>601412</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>PIETRO O TURILLI</PersonNm>
        <TitleTxt>SR. VP, EXTERNAL AFFAIRS (THRU 11/30/25)</TitleTxt>
        <BaseCompensationFilingOrgAmt>278491</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>76959</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>13235</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>36663</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>57901</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>463249</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>ROBERT LORETTE</PersonNm>
        <TitleTxt>SR. VP, BUSINESS DEVELOPMENT</TitleTxt>
        <BaseCompensationFilingOrgAmt>371624</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>96347</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>45767</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>44750</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>558488</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>SANDEEP JUNEJA</PersonNm>
        <TitleTxt>SR. VP, MARKET ACCESS</TitleTxt>
        <BaseCompensationFilingOrgAmt>343252</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>91836</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>43552</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>63915</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>542555</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>SALAH FORAIDA</PersonNm>
        <TitleTxt>SR. DIRECTOR, MEDICAL AFFAIRS</TitleTxt>
        <BaseCompensationFilingOrgAmt>386235</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>60204</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>44572</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>9591</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>500602</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>RAJNEESH TANEJA</PersonNm>
        <TitleTxt>VP, PHARMACEUTICAL PRODUCT DEVELOPMENT</TitleTxt>
        <BaseCompensationFilingOrgAmt>321485</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>70540</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>39002</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>45433</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>476460</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>KATHLEEN SCHOSTACK</PersonNm>
        <TitleTxt>SR. VP, PROGRAM &amp; ALLIANCE MANAGEMENT (THRU 08/31/25)</TitleTxt>
        <BaseCompensationFilingOrgAmt>220427</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>152582</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>6725</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>37540</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>26328</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>443602</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>SCHEDULE J, PART I, LINE 7 NON-FIXED PAYMENTS</FormAndLineReferenceDesc>
        <ExplanationTxt>VARIABLE COMPENSATION IS PAID TO STAFF MEMBERS BASED ON ANNUAL PERFORMANCE. REFER TO SCHEDULE O RESPONSE TO FORM 990, PART VI, SECTION B, LINES 15 A AND 15B FOR FURTHER DETAILS.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleJ>
    <IRS990ScheduleO documentId="IRS990ScheduleO" softwareId="25022866" softwareVersionNum="2025v4.2">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART III, LINE 4A PROGRAM SERVICE DESCRIPTION</FormAndLineReferenceDesc>
        <ExplanationTxt>SUTEZOLID - SUTEZOLID IS A PROMISING CLINICAL-STAGE TB DRUG CANDIDATE FROM THE OXAZOLIDINONE CLASS. TB ALLIANCE HAS IMPLEMENTED AN OPEN DEVELOPMENT APPROACH TO ADVANCE THE PHASE 2 TB DRUG CANDIDATE, SUTEZOLID, WHICH COULD BE A COMPONENT OF A NEXT-GENERATION TB REGIMEN. TB ALLIANCE HAS MADE SUTEZOLID AVAILABLE FOR STUDY BY ALL RESEARCHERS WHO COMMIT TO MAKING THEIR RESULTS AVAILABLE TO THE BROADER TB RESEARCH COMMUNITY. THIS NOVEL APPROACH HAS CONTRIBUTED TO THREE CLINICAL TRIALS THAT BEGAN IN 2023. PEERLINC - IN 2024, TB ALLIANCE LAUNCHED A NEW PEER-TO-PEER LEARNING FOR INNOVATIVE CURES (PEERLINC) KNOWLEDGE HUB BASED IN MANILA, WITH FUNDING FROM THE AUSTRALIAN GOVERNMENT THROUGH THE PARTNERSHIPS FOR A HEALTHY REGION INITIATIVE. PEERLINC, OPERATING IN PARTNERSHIP BETWEEN TB ALLIANCE AND THE TROPICAL DISEASE FOUNDATION, INC. (TDF), AND IN CLOSE COLLABORATION WITH THE DEPARTMENT OF HEALTH (DOH), PHILIPPINES, WILL HELP COUNTRIES IMPLEMENT BEST PRACTICES IN THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) TO HELP SPEED THE WORLDWIDE PROGRAMMATIC IMPLEMENTATION OF INNOVATIVE, MORE EFFECTIVE TREATMENTS FOR THE DISEASE, STARTING WITH THE WORLD HEALTH ORGANIZATION (WHO)-RECOMMENDED SIX-MONTH, ALL-ORAL BPAL/M REGIMENS, COMPOSED OF THE ANTIBIOTICS BEDAQUILINE (B), PRETOMANID (PA), AND LINEZOLID (L), WITH OR WITHOUT MOXIFLOXACIN (M). PEERLINC WILL PROVIDE PRACTICAL TRAINING AND TECHNICAL ASSISTANCE TO COUNTRIES TO SUPPORT THIS OBJECTIVE, VIA EXPERTS FROM THE PHILIPPINES AND THE DEPARTMENT OF HEALTH, INCLUDING LUNG CENTER OF THE PHILIPPINES AND THE NATIONAL TB REFERENCE LABORATORY (NTRL). THE PHILIPPINES HAS SUCCESSFULLY AND RAPIDLY DEPLOYED NEW TREATMENTS THROUGH PARTICIPATION IN TB ALLIANCE'S LEVERAGING INNOVATION FOR FASTER TB TREATMENT (LIFT-TB) INITIATIVE. IN 2024 ALONE, THE PEERLINC KNOWLEDGE HUB COMPLETED TRAININGS WITH LEADERS, EXPERTS, AND STAFF FROM NATIONAL TB PROGRAMS IN SEVEN COUNTRIES: PERU, DRC, NIGERIA, BRAZIL, CAMBODIA, TANZANIA, RWANDA. TO DATE, PEERLINC HAS TRAINED MORE THAN 50 COUNTRIES AROUND THE WORLD. G-TEC - AN INITIATIVE OF PEERLINC, G-TEC (GLOBAL TB EXPERT CONSULTATION) IS A DIGITAL ADVISORY PLATFORM CONNECTING FRONT-LINE PROVIDERS MANAGING DIFFICULT DR-TB CASES WITH EXPERTS ACROSS 18 COUNTRIES-TYPICALLY TURNING AROUND PRACTICAL GUIDANCE WITHIN 24 HOURS. LIFT-TB (LEVERAGING INNOVATION FOR FASTER TREATMENT OF TB) - THIS ACCESS PROGRAM, LAUNCHED IN 2020, SEEKS TO INCREASE TREATMENT COMPLETION RATES FOR DRUG-RESISTANT TB THROUGH ADOPTION AND SCALE UP OF NEW REGIMENS, BEGINNING WITH BPAL. IT FOCUSES ON SEVEN HIGH-BURDEN SOUTHEAST AND CENTRAL ASIAN COUNTRIES THAT SHOULDER APPROXIMATELY 1 IN 5 OF THE GLOBAL TB CASES. AS OF 2024, MORE THAN 100 COUNTRIES HAVE PROCURED THE SIX-MONTH, ALL-ORAL BPAL REGIMEN TO TREAT MORE THAN 180,000 PEOPLE WITH DRUG-RESISTANT TB. IN 2026, A NEW INDEPENDENT ANALYSIS SHOWED THAT LIFT-TB PLAYED A CRUCIAL ROLE IN ACCELERATING THE GLOBAL UPTAKE OF SHORTER, MORE EFFECTIVE TREATMENTS FOR DR-TB. THIS PROGRESS CONTRIBUTED TO A BROADER SHIFT IN HOW NEW TB TREATMENTS ARE INTRODUCED, HELPING REDUCE THE TIME FROM APPROVAL TO WIDESPREAD ACCESS FROM THE TYPICAL 7-9 YEARS TO APPROXIMATELY THREE YEARS. FAST TRACK THE CURE - IN SUPPORT OF THE WORLD HEALTH ORGANIZATION'S CALL TO ACTION TO ACCELERATE ACCESS TO SHORTER DR-TB CURES FOR ALL, THE FAST TRACK THE CURE MOVEMENT BRINGS COMMUNITIES AROUND THE WORLD TOGETHER TO RAISE AWARENESS AND FACILITATE ACCESS TO NEW DR-TB TREATMENTS, WHILE RAMPING UP ADVOCACY TO TELL WORLD LEADERS THAT SIX-MONTH DR-TB CURES MUST BE WIDELY ADOPTED AND AVAILABLE TO ALL WHO NEED THEM. FAST TRACK THE CURE IS ALSO COLLABORATING CLOSELY WITH STOP TB TO ENSURE STRATEGIC ALIGNMENT AND PARTNERSHIP AND WITH THE CHALLENGE FACILITY FOR CIVIL SOCIETY MOVEMENT, BY ALIGNING WITH THEIR COMMUNITY ENGAGEMENT, CAPACITY BUILDING, AND DEMAND CREATION PILLARS AND FOCUS. SLASH-TB - TB ALLIANCE AND THE SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE HAVE DEVELOPED SLASH-TB (SAVINGS FROM LEVERAGING &amp; ADOPTING SHORTER &amp; HIGHLY EFFECTIVE TB TREATMENTS), A MODEL TO ESTIMATE COST SAVINGS FOR HEALTH SERVICE SYSTEMS, PATIENTS, FAMILIES, AND/OR CAREGIVERS WHEN USING THE BPAL/M REGIMENS AS COMPARED TO STANDARD DRUG-RESISTANT TB TREATMENTS. UPSKILL TB -TB ALLIANCE, IN COLLABORATION WITH THE RPRI FOUNDATION AND INDONESIA'S MINISTRY OF HEALTH, HAS OFFICIALLY LAUNCHED THE UNIVERSAL PLATFORM FOR SKILL IMPROVEMENT AND LEARNING FOR NEW TB REGIMENS (UPSKILL TB) TO STRENGTHEN HEALTHCARE CAPACITY AND ACCELERATE THE FIGHT AGAINST DRUG-RESISTANT TUBERCULOSIS (DR-TB). THE LAUNCH EVENT TOOK PLACE IN JAKARTA AND WAS SHORTLY FOLLOWED BY A WORKSHOP LAUNCH AT THE 2025 UNION WORLD CONFERENCE ON LUNG HEALTH IN COPENHAGEN. UPSKILL TB IS A FLEXIBLE, AFFORDABLE, AND ACCESSIBLE DIGITAL LEARNING PLATFORM THAT HELPS ENSURE THAT HEALTHCARE PROFESSIONALS ACROSS INDONESIA, INCLUDING THOSE IN REMOTE REGIONS, ARE PREPARED TO DELIVER QUALITY CARE AND SUPPORT FOR PEOPLE UNDERGOING TREATMENT WITH NEW DR-TB REGIMENS. THE PLATFORM WILL BE ROLLED OUT TO ADDITIONAL COUNTRIES, INCLUDING UKRAINE AND CHINA IN 2026. MANAGE-TB - LAUNCHED AT THE 2025 UNION WORLD CONFERENCE ON LUNG HEALTH IN COPENHAGEN, MANAGE-TB IS A CLINICAL DECISION SUPPORT SYSTEM THAT HELPS PUBLIC AND PRIVATE CLINICIANS DELIVER GUIDELINE-ALIGNED CARE FOR COMPLEX DR-TB CASES, REDUCING VARIATION AND IMPROVING OUTCOMES. MANAGE-TB WAS BUILT BY TB ALLIANCE'S PARTNERS IN INDIA, AND THE TB ALLIANCE TEAM IS WORKING ON A NEW PROGRAM CALLED REGI-LINC THAT WILL HELP PROVIDE THIS SUPPORT SYSTEM MORE GLOBALLY. REGI-LINC IS ESTIMATED TO LAUNCH IN 2026.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, LINE 11B REVIEW OF FORM 990 BY GOVERNING BODY</FormAndLineReferenceDesc>
        <ExplanationTxt>FORM 990 WAS PREPARED BY A NATIONALLY RECOGNIZED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCE DEPARTMENT. THE DRAFT OF FORM 990 WAS REVIEWED BY THE ORGANIZATION'S FINANCE DEPARTMENT AND SENIOR MANAGEMENT, AND THEN PROVIDED TO ALL MEMBERS OF THE BOARD OF DIRECTORS IN DRAFT VIA ELECTRONIC MAIL, WITH AN OPPORTUNITY FOR THEM TO COMMENT OR MAKE INQUIRY BEFORE IT WAS FILED WITH THE INTERNAL REVENUE SERVICE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, LINE 12C CONFLICT OF INTEREST POLICY</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS DISTRIBUTED TO OFFICERS AND DIRECTORS ANNUALLY ALONG WITH A QUESTIONNAIRE THAT IS COMPLETED BY ALL OFFICERS AND DIRECTORS IN WHICH THEY ARE ASKED TO DISCLOSE INFORMATION REGARDING ACTUAL OR POTENTIAL CONFLICTS OF INTEREST. THESE QUESTIONNAIRES ARE COLLECTED AND REVIEWED ANNUALLY TO ENSURE COMPLIANCE WITH THE CONFLICT OF INTEREST POLICY. THE POLICY ITSELF ALSO REQUIRES ANY DIRECTOR OR OFFICER TO PROMPTLY DISCLOSE ANY CONFLICT OF INTEREST. INTERESTED DIRECTORS AND OFFICERS ARE REQUIRED TO RECUSE THEMSELVES FROM ANY DECISION ON MATTERS IN WHICH THEY HAVE AN INTEREST, AND SUCH RECUSAL IS NOTED IN THE MINUTES.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, LINE 15A PROCESS TO ESTABLISH COMPENSATION OF TOP MANAGEMENT OFFICIAL</FormAndLineReferenceDesc>
        <ExplanationTxt>THE COMPENSATION COMMITTEE, WHICH CONSISTS OF TWO INDEPENDENT BOARD MEMBERS, ANNUALLY REVIEWS THE CEO COMPENSATION IN CONJUNCTION WITH AN EVALUATION OF ORGANIZATIONAL PERFORMANCE. THE COMMITTEE RECOMMENDS ADJUSTMENTS IN COMPENSATION TO THE FULL BOARD FOR REVIEW AND APPROVAL, WITHIN THE CONTEXT OF AN AGREED UPON COMPETITIVE POSITION. THE COMPETITIVENESS OF COMPENSATION IS PERIODICALLY BENCHMARKED USING INDEPENDENT SALARY SURVEY DATA FROM THE NOT-FOR-PROFIT AND FOR-PROFIT INDUSTRY. THE COMPENSATION COMMITTEE DOCUMENTATION INCLUDES THE PERFORMANCE ASSESSMENT, COMPARABLE DATA AND THE SOURCE OF THIS DATA, AND THE RECOMMENDED ADJUSTMENTS. THE MINUTES OF THE FULL BOARD INCLUDE DOCUMENTATION OF THE APPROVED DECISIONS. THE MINUTES OF THE BOARD AND COMMITTEE ARE PREPARED BEFORE THE LATER OF THE NEXT MEETING OR 60 DAYS AFTER THE FINAL DECISION OF THE BOARD AND THE COMMITTEE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, LINE 15B PROCESS TO ESTABLISH COMPENSATION OF OTHER EMPLOYEES</FormAndLineReferenceDesc>
        <ExplanationTxt>THE COMPENSATION COMMITTEE, WHICH CONSISTS OF TWO INDEPENDENT BOARD MEMBERS, ANNUALLY REVIEWS OFFICERS COMPENSATION IN CONJUNCTION WITH AN EVALUATION OF ORGANIZATIONAL PERFORMANCE. THE COMMITTEE RECOMMENDS ADJUSTMENTS IN COMPENSATION TO THE FULL BOARD FOR REVIEW AND APPROVAL, WITHIN THE CONTEXT OF AN AGREED UPON COMPETITIVE POSITION. THE COMPETITIVENESS OF COMPENSATION IS PERIODICALLY BENCHMARKED USING INDEPENDENT SALARY SURVEY DATA FROM THE NOT-FOR-PROFIT AND FOR-PROFIT INDUSTRY. THE COMPENSATION COMMITTEE DOCUMENTATION INCLUDES THE PERFORMANCE ASSESSMENT, COMPARABLE DATA AND THE SOURCE OF THIS DATA, AND THE RECOMMENDED ADJUSTMENTS. THE MINUTES OF THE FULL BOARD INCLUDE DOCUMENTATION OF THE APPROVED DECISIONS. THE MINUTES OF THE BOARD AND COMMITTEE ARE PREPARED BEFORE THE LATER OF THE NEXT MEETING OR 60 DAYS AFTER THE FINAL DECISION OF THE BOARD AND THE COMMITTEE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART VI, LINE 19 REQUIRED DOCUMENTS AVAILABLE TO THE PUBLIC</FormAndLineReferenceDesc>
        <ExplanationTxt>THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART IX, LINE 11G OTHER FEES FOR SERVICES</FormAndLineReferenceDesc>
        <ExplanationTxt>PROFESSIONAL SERVICES AND AGREEMENTS INCLUDE INDIVIDUAL CONSULTANTS WHO ARE CONTRIBUTING THEIR SPECIFIC EXPERTISE RELATED TO OUR CLINICAL TRIALS AND OTHER EARLY STAGE AND PRECLINICAL DISCOVERY WORK. EXPERTISE IN SUCH AREAS AS PHARMACOVIGILANCE, NON-GLP BIOANALYSIS, ANALYTICAL EVALUATION OF DRUG STABILITY AND PROGRAM MANAGEMENT ARE SOME OF THE SERVICES REQUIRED IN ORDER TO COMPLETE OUR SCIENTIFIC RESEARCH AND DEVELOPMENT. THESE CONSULTANTS ARE MANAGED BY OUR STAFF, WHO COORDINATE THE WORK NECESSARY TO BE COMPLETED AMONG ALL OUTSIDE PARTIES.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART IX, LINE 11G OTHER FEES</FormAndLineReferenceDesc>
        <ExplanationTxt>OTHER PROFESSIONAL FEES - TOTAL EXPENSE: 6327742, PROGRAM SERVICE EXPENSE: 5823234, MANAGEMENT AND GENERAL EXPENSES: 294800, FUNDRAISING EXPENSES: 209708;</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>FORM 990, PART XI, LINE 9 OTHER CHANGES IN NET ASSETS OR FUND BALANCES</FormAndLineReferenceDesc>
        <ExplanationTxt>FOREIGN TRANSLATION LOSS - -44421; TOTAL - -44421;</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
  </ReturnData>
</Return>